Inventiva (NASDAQ:IVA) Trading Up 8.3% – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price was up 8.3% on Monday . The stock traded as high as $5.25 and last traded at $5.23. Approximately 462,445 shares were traded during mid-day trading, an increase of 15% from the average daily volume of 401,144 shares. The stock had previously closed at $4.83.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IVA. UBS Group initiated coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective for the company. Wall Street Zen upgraded Inventiva to a “hold” rating in a report on Saturday, October 18th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Inventiva in a research report on Tuesday, September 30th. Guggenheim decreased their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Inventiva currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Inventiva Trading Up 12.8%

The business’s fifty day moving average is $4.32 and its 200 day moving average is $4.48.

Institutional Trading of Inventiva

Several large investors have recently bought and sold shares of IVA. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Inventiva by 54.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of Inventiva during the third quarter worth $116,000. Millennium Management LLC acquired a new stake in shares of Inventiva during the third quarter valued at about $649,000. Finally, Creative Planning purchased a new stake in shares of Inventiva during the second quarter worth about $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.